BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/6/2023 10:35:23 AM | Browse: 434 | Download: 1614
 |
Received |
|
2022-12-21 14:06 |
|
Peer-Review Started |
|
2022-12-21 14:08 |
|
First Decision by Editorial Office Director |
|
2023-01-20 00:42 |
|
Return for Revision |
|
2023-01-20 00:42 |
|
Revised |
|
2023-02-01 15:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-03-20 03:15 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-03-20 09:19 |
|
Articles in Press |
|
2023-03-20 09:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-03-23 10:33 |
|
Publish the Manuscript Online |
|
2023-04-06 10:35 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qian Zou, Rui-Lin Shen, Xiao Guo and Chen-Ye Tang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Jiaxing Science and Technology Foundation |
2021AY30018 |
|
| Corresponding Author |
Chen-Ye Tang, Doctor, N/A, N/A, Department of Urology, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng Bei Lu, Nanhu District, Jiaxing 314001, Zhejiang Province, China. john99233@126.com |
| Key Words |
Prostate cancer; Chemotherapy; Prostate-specific antigen; Rectal tumor; Androgen deprivation therapy; Case report |
| Core Tip |
Chemotherapy is mainly used for castration-resistant prostate cancer (PC) (CRPC) and may also benefit patients with PC who have not progressed to CRPC. We describe a patient with high-risk locally advanced PC treated with laparoscopic radical prostatectomy plus short-term adjuvant hormonal therapy and rectal cancer treated with laparoscopic radical rectal resection plus adjuvant chemotherapy, and found that prostate-specific antigen declined after the capecitabine plus oxaliplatin chemotherapy. |
| Publish Date |
2023-04-06 10:35 |
| Citation |
Zou Q, Shen RL, Guo X, Tang CY. Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report. World J Clin Cases 2023; 11(11): 2528-2534 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i11/2528.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i11.2528 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
